Clinical Trial Update: Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea [Phase 4]

View source ↗

Summary

Phase 4 clinical trial completion evaluating whether a hydrogen breath test can predict response to rifaximin in irritable bowel syndrome with diarrhea.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome
• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: University of Michigan | Conditions: Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea | Phase 4 | Status: COMPLETED